Clinical trials in multiple sclerosis: Potential future trial designs by Manouchehri, Navid et al.











See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Authors
Navid Manouchehri, Yinan Zhang, Amber Salter, Rehana Z Hussain, Hans-Peter Hartung, Bernhard
Hemmer, Ralf Linker, Benjamin M Segal, Gary Cutter, and Olaf Stüve
https://doi.org/10.1177/1756286419847095 
https://doi.org/10.1177/1756286419847095
Therapeutic Advances in Neurological Disorders
journals.sagepub.com/home/tan 1
Ther Adv Neurol Disord
2019, Vol. 12: 1–10
DOI: 10.1177/ 
1756286419847095
© The Author(s), 2019.  
Article reuse guidelines:  
sagepub.com/journals-
permissions
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License  
(http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission 
provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction
Clinical trials in multiple sclerosis (MS) have 
been the cornerstone of drug development, lead-
ing to the introduction of an arsenal of disease-
modifying therapies (DMT) that has provided 
neurologists with a range of options for the treat-
ment of MS, thereby improving chances for a 
beneficial neurological outcome.1
The ultimate goal of a curative treatment for all 
patients with MS has not been achieved. Even 
today, with accurate early diagnosis, aggressive 
treatment, and vigilant clinical and paraclinical 
monitoring for breakthrough disease activity, a 
proportion of MS patients inevitably accumulate 
neurological disability and transition into a pro-
gressive disease course that is currently not 
responsive, or only marginally responsive, to 
approved pharmacotherapies. This calls for con-
tinued research to better understand the immu-
nopathological phenomena that drive disease 
activity, and to develop more effective interven-
tions based on this newly acquired knowledge. 
One approach toward understanding the patho-
genesis of MS is to investigate therapies targeted 
to specific patients in the context of clinical trials. 
A major question that remains is whether candi-
date treatments that do not seem to benefit MS 
patients are truly not effective, or whether the 
benefits are seen in areas not currently measured. 
There is a difference between those patients who 
fail based on current measures and those who 
may not appear to achieve benefits. Thus, the 
design of time-limited and budget-efficient phase 
III MS clinical trials faces unprecedented chal-
lenges that are due to the nature of the disease, 
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the availability of numerous DMTs, and the 
standard outcomes used.
The status quo and limitations of current 
trial designs
MS heterogeneity
Clinically, MS is a very heterogeneous disease 
with regard to age of onset, neurological manifes-
tations, relapse rates, and the rate at which neuro-
logical disability accumulates.2,3 Also, the disease 
course appears to differ between ethnic and racial 
patient populations.4 There is also heterogeneity 
in the diversity of pharmacological and immuno-
logical candidate putative molecular and cellular 
targets.5,6 Consequently, the challenge to identify 
the correct pharmacological agent for the correct 
patient population during the correct disease 
stage can be daunting.
It is currently thought that genetic susceptibil-
ity7–10 and environmental risk factors11–15 play a 
role in pathophysiology of MS. The extent of 
the involvement of specific factors in the initia-
tion and perpetuation of MS disease activity 
remains to be elucidated. Presumably, the initi-
ation of MS is not predicated on a singular and 
sudden event, but rather a series of genetically 
and proteomically permissive and environmen-
tally triggered events that become chronic and 
variable. The relative importance and combina-
tion of contributing genetic and environmental 
risk factors likely drive the variability of disease 
phenotypes among MS populations on individ-
ual and global scales. A meaningful and clini-
cally significant genetic association for central 
nervous system (CNS) autoimmunity among 
humans is currently limited to HLADRB1*15:01, 
which may also impact disease activity.16 Large 
genome-wide or exome screening assays have 
not been able to identify other risk alleles that 
have a meaningful impact on clinical disease 
onset or phenotype.17–19
Given the heterogeneity of clinical disease in 
patients with MS, different environmental factors 
may be critical in different populations. Globally, 
MS incidence varies across macro-geographical 
areas,20 and may be modulated by latitude and sun 
exposure,21 the degree of urbanization,22 the preva-
lence of certain infections,23 smoking,24 and other 
factors.25,26 Variability in neurological signs, relapse 
frequency, and the rate of disease progression 
results in a wide range of clinical phenotypes from 
benign relapsing MS with very limited progression 
over decades27–29 to primary progressive MS with 
relentless accumulation of disability and premature 
death.30–32 The MS spectrum is further compli-
cated by the introduction of subclinical MS, as seen 
in radiologically isolated syndromes (RIS)33 and 
the concept of MS prodrome.34–37 Differential 
treatment responses to DMTs in clinical trials and 
post-drug approval also constitute disease hetero-
geneity.38 This heterogeneity among MS patients 
illustrates an unmet need for more individualized 
treatment approaches through improved pharma-
cogenomic methods, which in turn will require 
objective molecular categorization of subclasses of 
MS patients.
Current problems in the clinical and 
paraclinical assessment of MS
Clinical and paraclinical MS has thus far been 
examined on a macro-anatomical scale both in 
terms of diagnosis and follow up of disease activ-
ity. MS is diagnosed when there is overt clinical 
disability accompanied by corroborating MRI 
abnormalities. Obvious flaws of this approach are 
delays in diagnoses and relatively frequent 
misdiagnoses.39–41
Current disease phenotypes are mostly based on 
clinical characteristics, and magnetic resonance 
imaging (MRI) of the brain as the paraclinical 
biomarker for further definition of these clinical 
phenotypes.42 However, currently utilized clinical 
and paraclinical tools for detection and monitor-
ing of MS are limited.
The Expanded Disability Status Scale (EDSS), as 
the main clinical scoring scale for MS disability 
assessment and estimation of disease progression, 
has a skewed reliance on measurable physical dis-
ability and primarily reflects ambulation status as 
the readout of physical deficits. However, neuro-
logical deficits secondary to MS span across func-
tional areas that are not easy to capture, including 
cognitive decline, sensory disturbances, and loss 
of motor dexterity.43 The EDSS only registers 
overt deficits and misses the subtle clinical dete-
riorations in the course of the disease as it is 
inherently limited by the sensitivity of the clinical 
examinations that constitute this scale.44 Finally, 
the EDSS records clinical information retrospec-
tively, but yields no information on disease 
progression.43,45
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Other disability scales, including the Multiple 
Sclerosis Functional Composite (MSFC), a 
three-part, standardized, quantitative assessment 
instrument that was developed to address some of 
the problems of the EDSS,46 was criticized by 
regulators for the uncertain clinical meaningful-
ness of the composite measure.
MRI as the main paraclinical assessment method 
in MS is also flawed due to its dependence on 
relatively large anatomical structural changes 
within the CNS. It is very likely that disease pro-
gression continues on a micro-level, driven by cel-
lular and molecular events beyond the sensitivity 
of MRI.44
Analyses of CSF specimens show oligoclonal 
bands (OCBs) in most patients. Composed of 
immunoglobulins, OCBs may suggest a patho-
genic role that autoreactive antigen-specific B 
cells play in MS. The presence of OCBs is a valu-
able tool in confirmation of MS diagnosis.47–49 
However, having no or little variability with dis-
ease activity or clinical disability, OCBs have little 
utility as a biomarker in clinical treatment trials.
Previous studies have assessed molecules for their 
ability to diagnose MS or provide predictive data. 
However, aside from recent novel observations 
on serum neurofilament light chain levels as a 
marker of disease activity and a tool to monitor 
treatment responses,50,51 most other biomarkers 
that have been studied lack sensitivity, specificity, 
and predictive value.44
Current problems with trial design in MS
Given the heterogeneity and diagnostic methods 
of MS, extensive clinical trial programs that entail 
very large numbers of patients and long durations 
are needed for each new agent to be tested and 
approved. In addition, with the availability of 
already-approved effective treatments, active 
comparator-controlled trial designs are now com-
monly employed, resulting in the need to recruit 
even larger cohorts with longer follow-up periods 
per trial than placebo-controlled studies before 
meaningful clinical and statistical differences can 
be reliably detected. As mentioned above, another 
issue is the lack of sensitivity and utility of pres-
ently employed clinical and paraclinical assess-
ments, which contributes to needing large 
numbers of patients and long-duration clinical 
trials in MS.
Clinically, and presumably pathogenetically, diverse 
patient populations are recruited to current MS 
clinical trials based on standard inclusion and exclu-
sion criteria. Consequently, negative or positive 
results may be driven by a particular subgroup, as 
suggested by post-hoc analyses.52,53 Nonresponders 
in study cohorts not only fail to receive the benefits 
of therapeutic interventions, but they also dilute 
positive signals from the responders in their cohort. 
Furthermore, data obtained from these studies are 
utilized to identify active comparator controls for 
future trials. Therefore, any bias from unrecog-
nized effects of nonresponders on clinical trial out-
comes often carry over to future assessments of 
novel therapies.
Finally, all investigations of new therapies are 
accompanied by a burden of risk for the study par-
ticipants through unexpected adverse reactions, or 
through the substantial delay in drug approval 
that may result from the current trial designs.
Requirements for novel trial designs
First, tangible goals should be articulated that 
allow the identification of well-defined study pop-
ulations and treatment responders through bio-
logical markers. These markers should allow the 
identification of likely treatment responders and 
nonresponders within clinical trial cohorts, and 
the verification of a response and nonresponse in 
validation cohorts. Such markers can be viewed 
as dynamic and sensitive surveillance methods 
that allow detection of positive response to DMTs 
in a given patient. Currently available examples 
include the visualization of MRI brain lesions and 
the quantification of cerebrospinal fluid (CSF) 
and blood neurofilament by digital enzyme-linked 
immunosorbent assay (ELISA).
Safety and effectiveness are the two main delivera-
bles of the clinical trials process. Pharmacological 
safety is relatively easily defined by the incidence of 
adverse effects and side-effects of a therapeutic 
intervention. The remainder of this article focuses 
on the definition of effectiveness, which is consid-
erably more challenging in MS.
To achieve approval of therapeutic interventions 
that are ideally suited for a defined patient popu-
lation, the goals should be the identification of 
biological markers that predict a meaningful clini-
cal response to each pharmacological agent in 
patient subgroups, to reduce the sample size of 
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the study population, to shorten the duration of 
the clinical trial, and to accelerate drug approval. 
Ideally, investigators will be able to group MS 
patients into objectively differentiable subclasses 
through these biological markers. Admittedly, 
this is a tall order in the face of the many treat-
ments available, and the lack of modern natural 
history data.
Novel candidates for MS biomarkers should meet 
the following criteria before they can achieve any 
advantage over current methods. A potential can-
didate biomarker should (1) reflect the underly-
ing pathophysiology of MS; (2) differentiate 
sensitively between the disease phenotypes in a 
prospective assessment of MS populations; (3) 
detect disease reactivation; and (4) provide relia-
ble data for a precise prediction of disease severity 
and prognosis. These criteria are difficult, but 
achievable, goals.
Endophenotypes in MS classification
Endophenotypes refer to subclasses present 
within one clinical diagnosis.54 They have various 
manifestations that are linked to underlying 
genetic and epigenetic differences between indi-
viduals.55 However, their divergence never 
exceeds the definitions of the background clinical 
syndrome. Since they are rooted in the genetic 
variations, endophenotypes are inheritable. Their 
effects are reflected through a matrix of biochemi-
cal molecules that are made or adjusted based on 
the genetic code. Biomarkers, defined as an objec-
tively measurable feature that differentiates 
between normal and pathologic states and 
responds to therapeutic interventions,56 are suit-
able candidates for (1) the disease diagnosis and 
(2) the identification of endophenotypes in dis-
ease populations. Such endophenotypes are rep-
resented through a meaningful shift in biomarkers 
compared with other disease subclasses that 
allows for disease monitoring.
The majority of previous biomarker studies in 
MS was hypothesis-driven and focused on the 
associations of MS clinical phenotypes with single 
biomarkers. In some instances, studies with wider 
scopes were able to draw conclusions from shifts 
in patterns of large biomarker groups within indi-
vidual MS patients or across MS populations.57
The multifactorial and complex pathogenesis of 
MS likely causes variable changes across a wide 
field of interdependent biomarkers that amount to 
system-level cascades of biochemical rearrange-
ments. Thus, implementation of a reductionist 
approach based on genomic and proteomic analy-
sis of biomarkers where type and number of meas-
ured variables are limited only by the overall power 
of the final model should be utilized to define 
objective MS endophenotypes. In this article, we 
utilize the term ‘disease classifying biomarkers’ 
(DCB) as a representation of a multivariable model 
based on multiple genomic and proteomic meas-
urements of biomarkers in MS biological samples.
Through novel proteomics assays, biomarker-
based categorization of MS subclasses suggest (1) 
stable intraindividual levels of MS-related bio-
markers in steady states; (2) meaningful differ-
ences in biomarker levels between healthy 
populations and MS patients; (3) variations in 
biomarker levels and ratios across different MS 
subclasses; and (4) an active response to MS pro-
gression and therapeutic interventions.57 These 
methods are still limited due to the noise that is 
inherent to spectroscopic prote-omics assess-
ments. In particular, the biomarker discovery 
phase often suffers from overfitting, meaning 
small samples on which a high number of tests is 
being conducted, and often without correction 
for multiple comparisons. These new strategies 
should be verified in controlled prospective vali-
dation studies.57,58
Prospective cohorts for endophenotype 
validations
The implementation of DCB-based endophe-
notype definition in MS classification is the pri-
mary requirement for the improvement of future 
MS trials. A variable disease spectrum is also 
likely with biomarker-based endophenotypes. 
For a new DCB-based MS disease spectrum to 
have any clinical significance, validation studies 
have to be undertaken to establish treatment 
response rates of patients within each endophe-
notype across the whole spectrum. Measuring 
DCBs through extensive -omics studies in 
patients with proven response to certain DMTs 
across the entire range of MS phenotypes deter-
mines the distribution of specific DCBs for each 
part of the disease spectrum. We hypothesize 
that suitable DCBs yield measurable predic-
tions in terms of prognosis and response to their 
corresponding treatments. Such predictions will 
require validation through demonstrable 
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correlations with MRI imaging outcomes and 
dynamic and sensitive disease markers, such as 
CSF and blood neurofilament levels in relatively 
short prospective studies among age- and 
comorbidity-adjusted patient cohorts. This will 
be a dynamic process that adds validated DCBs 
which, once validated, may replace their MRI 
and clinical assessment predecessors in future 
trial designs (Figure 1). Furthermore, in pro-
spective cohort studies treatment response data 
of each DMT can be analyzed against endophe-
notype subpopulations. By using the already 
established DCBs, current DMTs with the most 
effectiveness for each endophenotype will be 
determined (Figure 2).
Novel MS trial design
Prospective validation of DCB-based MS endo-
phenotypes in terms of treatment responses will 
allow new trial designs. This new concept would 
be especially useful in phase III trial designs where 
objective effectiveness benefits of novel therapies 
are weighed against currently approved DMTs. 
However, there needs to be some precautions and 
guidelines to consider in a DCB-based trial 
design. Simon and Maitournam’s discussion of 
targeted trial design points out that many factors 
impact the success for targeted designs, which fall 
under the rubric of precision medicine.59 First is 
the proportion of responsive patients, the accu-
racy of the assay identifying the targeted group, 
and the degree to which the mechanism of action 
is understood. They point out that when the 
group that tests positive for the biomarker is over 
50% of the population, the value of the targeted 
design is minimal, and the costs of screening and 
recruitment can outweigh any benefits. Similarly, 
unless there is marked differences in responsive-
ness between those with and without the bio-
marker, the targeted design may not be efficient 
since the larger sample size can overcome the 
mixing of the benefits between those with and 
without the biomarker by eliminating the need to 
screen and only randomize those with the 
biomarker.
Study goals: primary outcome measures
The study goals, as in any other new MS treat-
ment trial, should be the reduction or complete 
suppression of disease activity and the prevention 
and/or minimization of neurological deficit accu-
mulation in the shortest possible time span. In 
comparison with current outcome measures in 
MS trials, where studies look for relapse rate 
Figure 1. The definition of multiple sclerosis (MS) endophenotypes (EPs) will be based on response to 
disease-modifying therapies (DMTs) in prospective validating cohorts. Disease classifying biomarkers 
(DCBs) constitute the most reliable multivariate model recognizable from biomarker portfolios in each MS 
subpopulation. The implementation of new endophenotypes translates the current clinical and paraclinical 
subtypes of MS into finite biomarker-based MS endophenotypes.
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reduction, slowed disability worsening, stabiliza-
tion, or improvement, and a decrease in the num-
ber of brain MRI lesions and global or regional 
atrophy, biomarker-based outcomes could arrive 
at the same conclusion faster and with more 
reproducible results.
DCBs for each endophenotype will be used for 
establishment of effectiveness in comparison with 
previously available effective DMTs for the same 
endophenotype. The nature of direct measure-
ments of biomarkers provides a faster registration 
of response to treatment, but at the same time the 
additive power of measuring multiple biomarker 
variables in DCB models can be harnessed to 
arrive at a definitive conclusion of study outcomes 
in significantly less time compared with current 
designs.
This may afford what are called basket and 
bucket trials, where one mutation or molecular 
variation is studied with multiple drugs or one 
drug is applied to multiple mutations or molec-
ular variations. These trials may allow various 
approaches to treatment trials where multiple 
component trials are ongoing with the same 
infrastructure and same measurements, but the 
outcomes may differ, and/or the drugs and treat-
ments may differ.
Controls: randomization
Each new DMT will go through phase I and II 
trials where the most eligible endophenotypes for 
the new treatment are determined, before it is 
assessed in a phase III trial. Recruited control 
patients, randomized into an active comparator 
group, will also be selected from the same endo-
phenotypes. An enrichment trial design with 
noninferiority control model might be used to 
determine the effectiveness of the experimental 
treatment against a control population with the 
same disease endophenotype receiving the best 
alternative DMT evident by DCB responses 
(Figure 3). Alternatively, multiple treatments 
may be compared, dropping inferior treatments 
as they are identified with comparisons with 
cohorts of controls in what are called platform 
trials. Platform trials use a single protocol with 
multiple treatments evaluated. Adaptive plat-
form trials allow for dropping treatments for 
futility, superiority, or adding new treatments to 
be tested. They require extensive planning and 
cooperation on the part of the treatment provid-
ers, especially pharmaceutical companies who 
may feel they have too much at risk to partici-
pate. These approaches are admittedly novel in 
the field of MS. However, similar designs have 
been successfully implemented in other areas of 
clinical medicine, including oncology trials. The 
Figure 2. Endophenotype (EP)-based therapeutic interventions are most effective within their corresponding 
multiple sclerosis (MS) endophenotype.
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similarities of a DCB-based definition of endo-
phenotypes in MS to mutation-based models of 
cancer categorization provide plausibility for 
their potential success in MS. Very likely, DCB-
based MS endophenotypes will be inherently dif-
ferent from the strictly genetic basis of cancer 
subpopulations.60–62
Sampling population: sample size
The lowest number of inclusion criteria will allow 
more applicable or pragmatic clinical trials and 
will achieve the greatest generalizability. However, 
patient enrollment should include individuals 
with similar endophenotypes who will be identi-
fied at a screening DCB evaluation. To avoid 
confounding by prior treatment, it is ideal to have 
treatment-naïve patients with the desirable endo-
phenotypes randomly assigned to the experimen-
tal treatment group or an active comparator 
control. Since the DCB-based endophenotypes 
are reactive to DMT, biomarker-washout process 
should be validated for each DMT in comparison 
with treatment-naïve patients prior to study 
enrollments.
Selecting patients from within one endopheno-
type homogenizes the samples in the experimen-
tal treatment and control groups, reducing the 
variability among patients and thus allowing for 
detection of treatment differences with smaller 
sample sizes.
Furthermore, the shift from clinical outcome 
measures toward DCB-based assessments changes 
the framework of the minimum accepted changes 
for a clinical significance: The new variables will 
have considerably wider ranges resulting in a sig-
nificant drop in the required sample size. The 
combined effects of these two factors are poten-
tially strong enough to decrease the number of 
enrolled patients in the new trials. In current trial 
settings for MS, the heterogeneity of the patient 
population and DMT responses invokes the need 
for sample sizes of over 1000 patients. The hope 
with employing an endophenotype-based trial 
approach is to substantially diminish the number 
of patients that need to be enrolled to show a ben-
eficial effect of a therapeutic intervention.
Another factor that needs to be considered is the 
time to events or changes of interest. Even bio-
markers that are responsive and predictive may 
take some time to validate, optimize the timing of 
assessment, and/or even understand within the 
context of a statistical design, and thus affect the 
sample size.
Generalizability of the outcome
The final results of the study will be generalizable 
to all MS patients within the same endopheno-
type subclass that participated in the trial. As was 
noted above, this may depend on the homogene-
ity of prior therapy, if any, and other factors that 
Figure 3. New endophenotype (EP)-based multiple sclerosis (MS) trial design versus the status quo. 
Following an enrichment trial design, new disease-modifying therapies (DMTs) will be assessed against intra-
endophenotype patient-DMT controls.
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may coexist with these endophenotypes. However, 
it will be of critical importance that enrolled 
patients in the experimental treatment group or 
controls are of similar age, gender, and preexist-
ing comorbidities, for example, since these factors 
potentially confound biomarker-based readings 
through their effects on biochemical properties. 
The use of randomization produces comparable 
groups in the long run, but the reduction of sam-
ple sizes may also result in greater natural varia-
bility. This may lead to matching and/or stratifying 
and should be taken into account in the analyses.
By using similar endophenotypes, one might 
expect that the ‘nonresponder effect’ on the 
results will also be diminished, which provides 
greater reliability regarding other, similar study 
populations. DCB-based endophenotypes will 
likely be dynamic due to the administration of 
therapeutic agents and their potential effects on 
biomarkers, and due to the natural progression of 
the disease with changes in its biology. These 
changes could potentially move individual 
patients between endophenotypes. It will likely be 
necessary that treatment strategies and trial plan-
ning be tailored to patients over time and to assess 
the impact of these changes. A longer duration of 
clinical trials may increase the chance of such 
endophenotype changes.
Conclusion
Despite the progress that has been made in the 
field of MS therapeutics through the development 
and clinical testing of DMTs, the already hetero-
geneous MS population is further diversified 
through variable responsiveness to individual 
DMTs. Any novel and more effective DMT 
requires a significant superiority over previous 
treatments established through rigorous trials. 
However, treatments that may have specific effects 
that are of value over the long term may be missed 
by an aggregate result that looks like other stand-
ard therapies. An objectively universal measure 
will be required to be incorporated into the future 
MS trials that categorizes MS patients into homog-
enous subclasses. The hope of this approach is that 
statistical and clinical significance of clinical trials 
will be improved. A biomarker-based model of 
endophenotyping in MS populations using com-
pound genomics and proteomics patterns should 
provide a basis for faster and more reliable trial 
designs in MS populations. Studies for biomarker-
based models of endophenotyping in MS and 
validation studies required for utilization of such 
models in research should be considered a priority 
in MS research.
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